DRTX News Alert Durata Therapeutics Inc (DRTX) 24.16 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Durata Therapeutics Inc (DRTX) 24.16 $DRTX

XYDALBA(TM) (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults
PR Newswire - Fri Dec 19, 3:15PM CST
Actavis plc (NYSE: ACT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted Actavis' subsidiary Durata Therapeutics International, B.V., a positive opinion for XYDALBA (dalbavancin), for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
DRTX: 24.16 (+0.41), ACT: 254.20 (-1.68)

Merger Arbitrage Mondays - November 24, 2014
Asif Suria - at Seeking Alpha - Mon Nov 24, 4:38AM CST
Merger Activity decreased last week with five new mergers announced and five deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
DRTX: 24.16 (+0.41), ACT: 254.20 (-1.68), MONT: 22.59 (+0.26), CHYR: 2.78 (+0.02), TDY: 103.18 (+0.82), QRE: 14.35 (-0.50), HAL: 39.70 (-0.18), BBEP: 7.06 (-0.23), AGN: 210.12 (+0.95), LPDX: 5.24 (-0.01), BOLT: 21.99 (+0.01), VYFC: 19.73 (-0.07), BNCN: 17.43 (-0.24), LH: 107.69 (+0.56), OPLK: 24.23 (-0.03), BHI: 56.34 (-0.10)

ArQule (ARQL) Shows Strength: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:39AM CST
ArQule Inc. (ARQL) was a big mover last session, as its shares rose nearly 6% on the day.
DRTX: 24.16 (+0.41), LCI: 42.29 (+1.79), ARQL: 1.15 (+0.01), BIOD: 1.36 (-0.04)

Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 7:51AM CST
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as its shares rose over 6% on the day.
DRTX: 24.16 (+0.41), LCI: 42.29 (+1.79), ESPR: 35.97 (-0.08), BIOD: 1.36 (-0.04)

PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics
PR Newswire - Tue Nov 18, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that in connection with the acquisition of Durata Therapeutics, Inc. by Actavis, PDL has received approximately $42.7 million in connection with the termination of PDL's credit agreement with Durata, which included repayment of the full principal amount outstanding of $40 million, accrued interest, and prepayment and change of control premiums. In October 2013, PDL entered into a structured financing transaction with Durata in which PDL agreed to provide Durata with up to $70 million of debt financing with a five year term and in turn would receive interest on the principal amount outstanding and a security interest in substantially all of Durata's assets.
DRTX: 24.16 (+0.41), PDLI: 7.61 (unch)


Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), MRK: 57.46 (+0.25), VRX.TO: 162.98 (-0.62)

Actavis Rumored to be Close to Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:00AM CST
As per market rumors, Actavis (ACT) is closing in on a deal to acquire Allergan (AGN) for over $65.5 billion.
DRTX: 24.16 (+0.41), ZTS: 43.84 (+0.87), AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), VRX: 140.33 (-0.22)

Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
PR Newswire - Mon Nov 17, 7:00AM CST
Actavis plc (NYSE: ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata Therapeutics, Inc. (NASDAQ: DRTX), an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. As previously announced, Actavis offered to purchase all outstanding shares of Durata for $23.00 per share in cash, or approximately $675 million in the aggregate, and one contingent value right (CVR) per share, entitling the holder to receive additional cash payments of up to $5.00 per CVR if certain regulatory or commercial milestones related to Durata's lead product DALVANCETM are achieved.
DRTX: 24.16 (+0.41), ACT: 254.20 (-1.68)

5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 24.16 (+0.41), AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), IRWD: 14.57 (+0.25), CBST: 100.29 (-0.09), PFE: 31.42 (-0.03)

Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 24.16 (+0.41), AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), MDT: 74.08 (+0.31), SLXP: 114.92 (-1.18), SNY: 46.35 (+0.50)

Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 24.16 (+0.41), AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), SWKS: 74.32 (+0.92), AKRX: 36.47 (+0.43), JAZZ: 165.33 (+1.83), SLXP: 114.92 (-1.18), AAPL: 112.01 (-0.53), ATHM: 37.62 (-0.37)

Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata
PR Newswire - Fri Oct 31, 3:15PM CDT
Actavis plc (NYSE: ACT) and Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR" with respect to Actavis' pending acquisition of Durata.
DRTX: 24.16 (+0.41), ACT: 254.20 (-1.68)

SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection With the Sale of Durata Therapeutics, Inc. -- DRTX
GlobeNewswire - Wed Oct 29, 1:02PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Illinois Circuit Court on behalf of all common stockholders of Durata Therapeutics, Inc. ("Durata" or the "Company" (Nasdaq RTX) opposing the proposed acquisition of Durata by Actavis plc ("Actavis" .
DRTX: 24.16 (+0.41)

INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata Therapeutics Inc. Concerning the Fairness of the Sale of the Company to Actavis
Business Wire - Tue Oct 14, 11:37AM CDT
Levi & Korsinsky is investigating the Board of Directors of Durata Therapeutics Inc. ("Durata" or "the Company" (NASDAQ: DRTX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Actavis (NYSE:ACT).
DRTX: 24.16 (+0.41), ACT: 254.20 (-1.68)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Durata Therapeutics, Inc. in Connection with the Sale of the Company
Business Wire - Sat Oct 11, 6:05AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Durata Therapeutics, Inc. ("Durata" or the "Company" (Nasdaq: DRTX) relating to the proposed acquisition by Actavis plc.
DRTX: 24.16 (+0.41)

DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Durata Therapeutics Inc. (DRTX) Over the Proposed Sale of the Company to Actavis plc (ACT)
PR Newswire - Fri Oct 10, 5:45PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Durata Therapeutics Inc. ("Durata" or the "Company" (NasdaqGM: DRTX) for potential breaches of fiduciary duties in connection with the sale of the Company to Actavis plc for approximately $675 million. The Company's stockholders will only receive $23.00 for each share of Durata common stock they own, when according to Yahoo! Finance at least one analyst has set a price target of $26.00 for the Company. The deal price might be $5.00 higher based on a contingency-milestone basis.
DRTX: 24.16 (+0.41)

DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Fri Oct 10, 4:31PM CDT
Rigrodsky & Long, P.A.:
DRTX: 24.16 (+0.41), ACT: 254.20 (-1.68)

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Fri Oct 10, 4:25PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Durata Therapeutics, Inc. (NASDAQ: DRTX), ("Durata" or the "Company" relating to the proposed buyout of the Company by Actavis plc ("Actavis" .
DRTX: 24.16 (+0.41)

Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM)
GlobeNewswire - Fri Oct 10, 1:04PM CDT
Durata Therapeutics (Nasdaq RTX) today announced a summary of presentation data from its recently launched product, DALVANCE(TM) (dalbavancin) for injection. The data were presented in five posters at IDWeek 2014, which took place from October 8-11, 2014 in Philadelphia, PA. Among the findings, a study of pharmacokinetic activity in bone and associated tissues demonstrated that dalbavancin accumulates in bone and supports further study in patients with osteomyelitis and prosthetic joint infections. A separate analysis showed patients with ABSSSI who were treated with dalbavancin had similar clinical success rates to those treated with IV vancomycin alone, as well as a tendency to have fewer adverse events and less nephrotoxicity compared to patients who received IV vancomycin for greater-than or equal to10 days. An examination of ASO and DNase-B titers in patients with streptococcal skin infections in the dalbavancin DISCOVER program was also presented.
DRTX: 24.16 (+0.41)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 302

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 72

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Future of Energy: Upgrading America's Aging Power Grid

Updated Category News Views 219

The Energy Conundrum Let’s face it, folks, the electric grid we’re using is like a beat-up old car—driving it won’t get any easier unless we pour in some cash and elbow grease. We all know increasing demand for power is putting the squeeze on the infrastructure, and everybody from policymakers to average homeowners is feeling the pinch. Do a little research (or...

Continue Reading
Cove Capital Investments Boosts Annual Distribution Rates Again

Updated Category News Views 69

Cove Capital Investments Announces Distribution Rate Increase The recent announcement regarding the increase in distribution rates by Cove Capital Investments highlights the success of its unique value-add strategy. This strategy is elaborated in the Private Placement Memorandum when the multifamily offering was made available to accredited investors. Performance of Cove...

Continue Reading
Broadcom Surges in After-Hours Trading on Stellar Earnings

Updated Category News Views 268

Broadcom Inc Reports Strong Earnings Broadcom Inc (NASDAQ: AVGO) experienced a remarkable 12.82% increase in its shares during after-hours trading after unveiling its first-quarter results. This rally followed a 6.33% decline during the regular trading hours, which was part of a larger trend of selloffs in the artificial intelligence (AI) chip market. Significant...

Continue Reading
Recent Downgrades: Analysts Weigh In on Key Stocks

Updated Category News Views 162

Analysts' Outlook on Key Stocks Recent changes from top Wall Street analysts revealed a shift in outlook on several prominent companies. Their evaluations often impact market trends and investor sentiment towards various stocks. Invivyd Inc Downgraded D. Boral Capital's Jason Kolbert downgraded the rating for Invivyd Inc (NASDAQ: IVVD) from Buy to Hold. On the trading...

Continue Reading
Innovative Grip Module Redefines Firearm Handling Experience

Updated Category News Views 299

Revolutionizing Firearm Grip with Innovative Design In the realm of firearm accessories, innovation often leads to transformative user experiences. One such breakthrough comes in the form of the 2911 Grip Module. This specially designed grip module addresses the common issues faced by firearm enthusiasts, offering a solution that enhances both comfort and usability. What...

Continue Reading